Navigation Links
Royalty Pharma Announces Proposal To Acquire Elan
Date:2/25/2013

NEW YORK, Feb. 25, 2013 /PRNewswire/ -- RP Management, LLC ("Royalty Pharma") today announces that contact was made on Monday February 18, 2013 with the Chairman of the Board of Elan Corporation, plc (NYSE: ELN) ("Elan"), followed by a meeting then taking place on Wednesday February 20, 2013, at which an indicative proposal was made to acquire the entire issued and to be issued share capital of Elan (the "Proposal").

Royalty Pharma is proposing, on an indicative basis, to make an offer for Elan (the "Possible Offer") of US$11[1] for every Elan Share and every Elan ADS.

While Royalty Pharma has not received a formal response to its Proposal and has been unsuccessful in its efforts to engage with Elan since making the Proposal, Royalty Pharma remains committed to working towards a recommended transaction. Royalty Pharma was, however, surprised by Elan's public announcement on Friday February 22, 2013 discussing Elan's standalone strategy but not addressing the fact that Elan had received Royalty Pharma's Proposal.

Royalty Pharma's Proposal offers Elan Shareholders a simple and clear choice:

  • Remain an investor in a company whose material assets (in the context of the assets of the Elan Group, taken as a whole), following the completion of the Tysabri Transaction, will consist of cash and the Tysabri Royalty while Elan's management pursues its announced strategy which includes maintaining expected operating expenses in the range of US$170-190 million[2] in the 2013 financial year and investing in a variety of yet-to-be-disclosed business assets; or
  • Sell their Elan Stock for a cash amount that Royalty Pharma believes reflects the full value of Elan today.
  • Royalty Pharma believes that the risks and lack of earnings visibility associated with Elan's acquisition and in-licensing strategy are substantial. The pharmaceu
    '/>"/>

    SOURCE Royalty Pharma
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Royalty Rates Take Center Stage in Biopharma Dealmaking
    2. Reckitt Benckiser Pharmaceuticals Inc. Receives FDA Response to Citizens Petition
    3. Health Outcomes Liaisons (HOLs) Serve as Key Bridge between Pharmaceutical Sector and Managed Care Groups
    4. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
    5. State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
    6. Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2012
    7. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
    8. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
    9. Promise and Problems Signal Mixed Year Ahead for Biopharmaceutical Industry, Says Pharmaceutical Executive Magazine
    10. Webcast Alert: Isis Pharmaceuticals 2012 Financial Results and Highlights Conference Call
    11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
    (Date:8/31/2015)... -- Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: ... of delivering its patented (US Patent 8,263,571) gene ... a clinically approved formulation as delivery system.  The ... silencing therapeutics in which the gene silencing drug ... By utilizing a local delivery system, potential toxicities ...
    (Date:8/31/2015)... TEL AVIV, Israel , August 31, 2015 ... Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" ... manages and commercializes biomedical innovations in ophthalmology and ... subsidiary, Micromedic Technologies (TASE: MCTC), has identified several ... necrosis of the jawbone in patients treated with ...
    Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4
    ... Baby Girl with Hypophosphatasia Treated With ENB-0040 at Children,s ... , MONTREAL, Dec. 1 Enobia ... novel therapeutics for serious bone disorders, today announced that ... hypophosphatasia was dosed. Enobia is investigating Enzyme Replacement Therapy ...
    ... Genaera Corporation (Nasdaq: GENR ) today ... MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b ... 2 diabetics. MSI-1436 is a novel therapeutic for the ... centrally and peripherally to regulate insulin and leptin pathways ...
    Cached Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3
    (Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law ... William Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... percent of attorneys in the state of Illinois. The nomination process is based on ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about ... who are interested in learning more about the procedure beyond the information found on ... Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand to answer patients ...
    (Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric Disease and Treatment ... on transcranial near-infrared laser phototherapy ”. , As corresponding author Dr Theodore Henderson ... untreatable - with mostly palliative treatments only - and now we have shown ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine & Sports ... Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle and foot. ... system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ankle and ...
    (Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
    Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
    ... For the fourth,consecutive year, the Surf City USA(R) Marathon ... for a fundraising event that is directly,responsible for changing the ... In the Fourth Annual "Run for Mobility", ... Marathon and 5K as a way to raise funds,that sends ...
    ... general is boosting rates of obesity, other woes, experts ... a strong link between media exposure and childhood obesity, ... reviewed 173 studies on media and health conducted over ... 80 percent of the studies concluded that higher amounts ...
    ... "frozen lozenge" provides breakthrough method to help medicine go down , ... "A spoonful of sugar helps the medicine go down" -- parents ... Insight Pharmaceuticals has introduced Sucrets(R) ICE -- unique, frozen single-use packages ... sore throats. , , ...
    ... Med (IM) welcomes new CEO, S.,Hart Williford. Williford joins ... extensive background as a leader in healthcare,software, revenue management, ... Founder and nine-year CEO, Dr. ... and development in all sectors, as he steps into,the ...
    ... can affect whole families, experts point out , , TUESDAY, Dec. ... toll not only on women,s wallets but on their health ... back on health care due to costs, according to a ... Resource Center, part of the U.S. Department of Health and ...
    ... Science, and Technology at the Sandra Day O,Connor College ... international conference on April 3-4, 2009, in Tempe, Ariz., ... to the highly anticipated report of the U.S. National ... Sciences Community." , In addition to experts from ...
    Cached Medicine News:Health News:Surf City USA(R) Marathon Impacts the World 2Health News:TV, Internet Causing Kids Harm: Report 2Health News:New Sucrets(R) ICE Cools Sore Throat Pain 2Health News:Ingenious Med Hires New CEO to Maintain and Further Expand Company Development 2Health News:Economy Driving Women to Skimp on Health Care: Poll 2Health News:Economy Driving Women to Skimp on Health Care: Poll 3
    The KM-500's unique viewing and alignment window lets you observe the targeted eye from any distance. Two rechargeable batteries provide continuous uninterrupted use. Each battery provides 60 minutes...
    Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
    ... Provides quick freezing and quick ... gas system - cleans the ... Lightweight probe tips have high ... Retinal Detachment, Glaucoma and Intra-vitreal ...
    ... instant defrosting by reversible flow of gas ... cycle automatically. Lightweight probe tips have high ... I/A. The surgeon can select either of ... Surgeon can have a selection of Irrigation, ...
    Medicine Products: